2021 Midyear Review: Non–Small-Cell Lung Cancer

Supported through funding from 
Bristol Myers Squibb

This material is divided into the following topic areas:

2021 Midyear Review: Non–Small-Cell Lung Cancer

Researchers and clinicians continue to make advances in the treatment of cancer. In 2021, despite the COVID-19 pandemic, there have been many exciting developments in biomarker testing and other diagnostics, treatment approaches and targets, and other aspects of cancer care.